Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HKCOV trial of kakkonto plus hochuekkito for preventing worsening of mild COVID-19
jRCTs041200072Completed
- Sponsor
- Tsumura & Co.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of kakkonto and buzhong yiqi in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tsumura & Co. Primary endpoint: Ratio of worsening within 10 days after test drug administration. Started Dec 2020; status: completed.
02
Drugs
kakkontobuzhong yiqi
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs041200072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200072.